ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

DXRX Diaceutics Plc

104.00
0.00 (0.00%)
12 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Diaceutics Plc LSE:DXRX London Ordinary Share GB00BJQTGV64 ORD GBP0.002
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 104.00 103.00 105.00 104.50 104.00 104.00 10,813 08:00:22
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Testing Laboratories 19.5M 724k 0.0086 120.93 87.85M

Diaceutics PLC Expanded lab network and data capabilities

27/02/2024 7:00am

RNS Regulatory News


RNS Number : 5258E
Diaceutics PLC
27 February 2024
 

Diaceutics grows its lab network and data capabilities in Europe

 

New data will deliver enhanced insights to Diaceutics' customers and drive new sales opportunities across multiple geographies

 

Belfast and London, 27 February 2024 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, is pleased to announce it has expanded its data supply network which will significantly increase the number of labs through which Diaceutics is sourcing data in Europe and will broaden the Company's European data coverage. This data will accelerate the rollout of the DxRx Signal product in key EU markets of Germany, France, Italy, Spain and the United Kingdom (DxRx Signal has only previously been offered by Diaceutics in the US market).

The increased data is now available to Diaceutics customers enabling them to find more patients eligible for their new and innovative therapies.

Jordan Clark, Chief Data Officer of Diaceutics commented: "This data will further endorse our position as a leading provider of data to biotech and pharma companies as they commercialize their products, find and deliver therapies to patients across multiple geographies."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR. The person responsible for making this announcement on behalf of the Company is Nick Roberts, Chief Financial Officer. 

 

Enquiries: 

Diaceutics PLC  

 Tel: +44 (0)28 9040 6500 

Ryan Keeling, Chief Executive Officer 

Nick Roberts, Chief Financial Officer

Jordan Clark, Chief Data Officer  

investorrelations@diaceutics.com 



Stifel Nicolaus Europe Limited (Nomad & Broker) 

Tel: +44 (0)20 7710 7600 

Ben Maddison 


Nick Harland 

Kate Hanshaw 




Alma Strategic Communications 

Tel: +44 (0)20 3405 0205 

Caroline Forde 

diaceutics@almastrategic.com 

Kinvara Verdon 


 

About Diaceutics 

At Diaceutics we believe thatevery patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX - The Diagnostics Network ®.

  

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDXGDDDBDDGSL

1 Year Diaceutics Chart

1 Year Diaceutics Chart

1 Month Diaceutics Chart

1 Month Diaceutics Chart

Your Recent History

Delayed Upgrade Clock